Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

40.93 -0.43 (-1.04%)
Streaming Delayed Price Updated: 1:50 PM EDT, May 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap
From Guardant Health, Inc.
Via Business Wire
4 Analysts Have This To Say About Guardant Health
Via Benzinga
Guardant Health: Q4 Earnings Insights
Via Benzinga
Decoding 4 Analyst Evaluations For Guardant Health
Via Benzinga
Cancer Test Focused Guardant Health Stock Falls On FDA AdCom Update For Colorectal Test
Guardant Health surpasses Q4 2023 revenue expectations, reporting $155.1 million. Precision oncology revenue is up 25% to $142.2 million. Adjusted EPS loss beats consensus. Update on Shield CRC... 
Via Benzinga
Exposures Product Safety
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
From Guardant Health, Inc.
Via Business Wire
What 7 Analyst Ratings Have To Say About Guardant Health
Via Benzinga
3 Stocks to Buy for the Age of Personalized Medicine
Personalized medicine stocks can unlock significant growth from your portfolio. Here are three companies to consider. 
Via InvestorPlace
Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
From Guardant Health, Inc.
Via Business Wire
Bull of the Day - NeoGenomics
But in late December, shares took a big hit on patent litigation with competitor Natera. Let's review the primary commercial business of NEO and then that will help put the legal news into context. 
Via Talk Markets
Topics Intellectual Property
Exposures Intellectual Property
7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024
Small cap stocks are anticipated to rise by as much as 50% in 2024 as investors look for growth in new areas of the market. 
Via InvestorPlace
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results
From Guardant Health, Inc.
Via Business Wire
4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024
Even if Wall Street is wrong about these stocks in the new year, Cathie Wood could still be right about them over the long run. 
Via The Motley Fool
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
From Guardant Health, Inc.
Via Business Wire
Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Blood-Based Colorectal Cancer CRC Screening Market Likely to Benefit From FDA's Panel Surprise Advisory Possibility: Analyst
Tuesday, Guardant Health Inc (NASDAQ: GH) announced that the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the premarket... 
Via Benzinga
Exposures Product Safety
S&P 500, Nasdaq Set For Weaker Open As 'FOMO' Rally Cools: Analyst Says Only 'Black Swan Could Upset Santa's Sleigh' Now
Bond yields remain contained, providing a reason for traders to maintain their investments in stocks. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test
From Guardant Health, Inc.
Via Business Wire
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities
From Guardant Health, Inc.
Via Business Wire
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
From Guardant Health, Inc.
Via Business Wire
Jim Cramer: Buy This Financial Stock, 'It's Up Substantially From Where It Was In The Spring'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he remains a buyer of SoFi Technologies, Inc. (NASDAQ: SOFI). 
Via Benzinga
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
Why Is Cancer Blood Test-Focused Guardant Health Stock Trading Lower Today?
Guardant Health Inc (NASDAQ: GH) shares are falling after the company announced it intends to appeal its verdict in the U.S. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback